Aug. 19 at 2:25 PM
$ZVRA A week ago, I mused on the meteoric rise of Soleno Therapeutics on the back of its FDA approved ultra-rare disease drug VYKAT as a treatment for Prader-Willi Syndrome. It was quickly snatched up at a premium by Neurocrine Biosciences (
$NBIX).
Since then, I haven’t been able to stop thinking of them as a possible suitor of Zevra in order to acquire MIPLYFFA in NPC. BioSpace, highlighted a serious problem with VYKAT recently by reporting 7 possibly drug related deaths and 100 serious adverse events. https://www.biospace.com/drug-development/deaths-reported-after-treatment-with-neurocrines-approved-prader-willi-drug
NASDAQ protects the equities under its ☂️ by showcasing them in time of need at opening bell ceremonies. Neurocrine enjoyed that honor yesterday.
For all of its problems MIPLYFFA has a relatively benign side-effect profile highlighted mostly by manageable respiratory issues. An all stock buyout bringing in
$260M and immediate revenue has to be glitteringly attractive.
